Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO). A personalized tumorogram for each patient will be provided, based on the results of the drug screening (= tumor predicted as sensitive, intermediate, resistant or non-evaluable for each drug tested). Patients with an informative tumorogram will receive one of the recommended treatments (line N+1) in the event of tumor progression, administered according to standard procedures and validated at medical meetings specific to each center, and their fate will be monitored.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby powyżej 18 roku życia
- •Zaawansowany rak piersi
- •Określony typ raka piersi (potrójnie ujemny lub hormonozależny po leczeniu)
- •Rak, którego wielkość można zmierzyć i można pobrać jego fragment do badania
- •Dobry ogólny stan zdrowia pozwalający na leczenie
✗ Disqualifies
- •Wcześniej otrzymane więcej niż 3 linie chemioterapii w zaawansowanym stadium raka
- •Aktywne przerzuty do mózgu
- •Przerzuty do opon mózgowych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Institut Curie
Paris, France
Hôpital Saint-Louis - AP-HP Senopole
Paris, France
Institut Curie
Saint-Cloud, France
Trial contact
Luc CABEL, MD
Anne-Sophie Plissonnier
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.